NCT01777217View on ClinicalTrials.gov

VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate

PHASE4TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Over-Active Bladder
Interventions
DRUG

Solifenacin succinate

IGRT with VESIcare

DRUG

Placebo

IGRT with placebo

Trial Locations (1)

77025

Century Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Advanced Research Network

INDUSTRY

NCT01777217 - VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate | Biotech Hunter | Biotech Hunter